Report Detail
Global Anti-epileptic Drugs for Pediatrics Market Insights, Forecast to 2025
- RnM2888448 |
- 17 June, 2019 |
- Global |
- 113 Pages |
- QYResearch |
- Pharma & Healthcare
Epilepsy is associated with disrupted activities in the brain called seizures, which affects the central nervous system. Depending on the area of the brain obstructed by seizures, these are categorized into generalized seizures and partial seizures. Generalized seizures affect the whole brain, while partial seizures affect just one part of the brain. Depending on their severity, seizures are termed as mild seizures and stronger seizures. Mild seizures are difficult to diagnose, as these last for only a few seconds. Stronger seizures may last for a few seconds to a few or several minutes, resulting in spasms and uncontrollable muscle twitches. This may cause the patient to lose consciousness, lead to temporary loss of cognition, or memory loss during the seizure. Pediatric epilepsy can be caused due to a trauma injury, complications during birth, or genetic disorder. Epilepsy that occurs due to brain infections such as meningitis is known as symptomatic epilepsy, while genetics related condition is called idiopathic epilepsy.
The global Anti-epileptic Drugs for Pediatrics market is valued at 830 million US$ in 2018 and will reach 1530 million US$ by the end of 2025, growing at a CAGR of 7.9% during 2019-2025. The objectives of this study are to define, segment, and project the size of the Anti-epileptic Drugs for Pediatrics market based on company, product type, end user and key regions.
This report studies the global market size of Anti-epileptic Drugs for Pediatrics in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Anti-epileptic Drugs for Pediatrics in these regions.
This research report categorizes the global Anti-epileptic Drugs for Pediatrics market by top players/brands, region, type and end user. This report also studies the global Anti-epileptic Drugs for Pediatrics market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.
The following manufacturers are covered in this report, with sales, revenue, market share for each company:
Mylan N.V
Cephalon, Inc
GlaxoSmithKline plc
Janssen Pharmaceuticals
Novartis AG
Pfizer, Inc
Sanofi S.A
UCB Pharma Limited
Sunovion Pharmaceuticals Limited
Valeant Pharmaceuticals International, Inc
Zogenix
GW Pharmaceuticals
Insys
Zynerba
Market size by Product
1st generation
2nd generation
3rd generation
Market size by End User
Hospitals
Retail pharmacies
Online pharmacies
Market size by Region
North America
United States
Canada
Mexico
Asia-Pacific
China
India
Japan
South Korea
Australia
Indonesia
Singapore
Malaysia
Philippines
Thailand
Vietnam
Europe
Germany
France
UK
Italy
Spain
Russia
Central & South America
Brazil
Rest of Central & South America
Middle East & Africa
GCC Countries
Turkey
Egypt
South Africa
The study objectives of this report are:
To study and analyze the global Anti-epileptic Drugs for Pediatrics market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.
To understand the structure of Anti-epileptic Drugs for Pediatrics market by identifying its various subsegments.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
Focuses on the key global Anti-epileptic Drugs for Pediatrics companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.
To project the value and sales volume of Anti-epileptic Drugs for Pediatrics submarkets, with respect to key regions.
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
In this study, the years considered to estimate the market size of Anti-epileptic Drugs for Pediatrics are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
This report includes the estimation of market size for value (million US$) and volume (K Units). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Anti-epileptic Drugs for Pediatrics market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.
For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.
Table of Contents
1 Study Coverage
- 1.1 Anti-epileptic Drugs for Pediatrics Product
- 1.2 Market Segments
- 1.3 Key Manufacturers Covered
- 1.4 Market by Type
- 1.4.1 Global Anti-epileptic Drugs for Pediatrics Market Size Growth Rate by Product
- 1.4.2 1st generation
- 1.4.3 2nd generation
- 1.4.4 3rd generation
- 1.5 Market by End User
- 1.5.1 Global Anti-epileptic Drugs for Pediatrics Market Size Growth Rate by End User
- 1.5.2 Hospitals
- 1.5.3 Retail pharmacies
- 1.5.4 Online pharmacies
- 1.6 Study Objectives
- 1.7 Years Considered
2 Executive Summary
- 2.1 Global Anti-epileptic Drugs for Pediatrics Market Size
- 2.1.1 Global Anti-epileptic Drugs for Pediatrics Revenue 2014-2025
- 2.1.2 Global Anti-epileptic Drugs for Pediatrics Sales 2014-2025
- 2.2 Anti-epileptic Drugs for Pediatrics Growth Rate by Regions
- 2.2.1 Global Anti-epileptic Drugs for Pediatrics Sales by Regions
- 2.2.2 Global Anti-epileptic Drugs for Pediatrics Revenue by Regions
3 Breakdown Data by Manufacturers
- 3.1 Anti-epileptic Drugs for Pediatrics Sales by Manufacturers
- 3.1.1 Anti-epileptic Drugs for Pediatrics Sales by Manufacturers
- 3.1.2 Anti-epileptic Drugs for Pediatrics Sales Market Share by Manufacturers
- 3.1.3 Global Anti-epileptic Drugs for Pediatrics Market Concentration Ratio (CR5 and HHI)
- 3.2 Anti-epileptic Drugs for Pediatrics Revenue by Manufacturers
- 3.2.1 Anti-epileptic Drugs for Pediatrics Revenue by Manufacturers (2014-2019)
- 3.2.2 Anti-epileptic Drugs for Pediatrics Revenue Share by Manufacturers (2014-2019)
- 3.3 Anti-epileptic Drugs for Pediatrics Price by Manufacturers
- 3.4 Anti-epileptic Drugs for Pediatrics Manufacturing Base Distribution, Product Types
- 3.4.1 Anti-epileptic Drugs for Pediatrics Manufacturers Manufacturing Base Distribution, Headquarters
- 3.4.2 Manufacturers Anti-epileptic Drugs for Pediatrics Product Type
- 3.4.3 Date of International Manufacturers Enter into Anti-epileptic Drugs for Pediatrics Market
- 3.5 Manufacturers Mergers & Acquisitions, Expansion Plans
4 Breakdown Data by Product
- 4.1 Global Anti-epileptic Drugs for Pediatrics Sales by Product
- 4.2 Global Anti-epileptic Drugs for Pediatrics Revenue by Product
- 4.3 Anti-epileptic Drugs for Pediatrics Price by Product
5 Breakdown Data by End User
- 5.1 Overview
- 5.2 Global Anti-epileptic Drugs for Pediatrics Breakdown Data by End User
6 North America
- 6.1 North America Anti-epileptic Drugs for Pediatrics by Countries
- 6.1.1 North America Anti-epileptic Drugs for Pediatrics Sales by Countries
- 6.1.2 North America Anti-epileptic Drugs for Pediatrics Revenue by Countries
- 6.1.3 United States
- 6.1.4 Canada
- 6.1.5 Mexico
- 6.2 North America Anti-epileptic Drugs for Pediatrics by Product
- 6.3 North America Anti-epileptic Drugs for Pediatrics by End User
7 Europe
- 7.1 Europe Anti-epileptic Drugs for Pediatrics by Countries
- 7.1.1 Europe Anti-epileptic Drugs for Pediatrics Sales by Countries
- 7.1.2 Europe Anti-epileptic Drugs for Pediatrics Revenue by Countries
- 7.1.3 Germany
- 7.1.4 France
- 7.1.5 UK
- 7.1.6 Italy
- 7.1.7 Russia
- 7.2 Europe Anti-epileptic Drugs for Pediatrics by Product
- 7.3 Europe Anti-epileptic Drugs for Pediatrics by End User
8 Asia Pacific
- 8.1 Asia Pacific Anti-epileptic Drugs for Pediatrics by Countries
- 8.1.1 Asia Pacific Anti-epileptic Drugs for Pediatrics Sales by Countries
- 8.1.2 Asia Pacific Anti-epileptic Drugs for Pediatrics Revenue by Countries
- 8.1.3 China
- 8.1.4 Japan
- 8.1.5 Korea
- 8.1.6 India
- 8.1.7 Australia
- 8.1.8 Indonesia
- 8.1.9 Malaysia
- 8.1.10 Philippines
- 8.1.11 Thailand
- 8.1.12 Vietnam
- 8.1.13 Singapore
- 8.2 Asia Pacific Anti-epileptic Drugs for Pediatrics by Product
- 8.3 Asia Pacific Anti-epileptic Drugs for Pediatrics by End User
9 Central & South America
- 9.1 Central & South America Anti-epileptic Drugs for Pediatrics by Countries
- 9.1.1 Central & South America Anti-epileptic Drugs for Pediatrics Sales by Countries
- 9.1.2 Central & South America Anti-epileptic Drugs for Pediatrics Revenue by Countries
- 9.1.3 Brazil
- 9.2 Central & South America Anti-epileptic Drugs for Pediatrics by Product
- 9.3 Central & South America Anti-epileptic Drugs for Pediatrics by End User
10 Middle East and Africa
- 10.1 Middle East and Africa Anti-epileptic Drugs for Pediatrics by Countries
- 10.1.1 Middle East and Africa Anti-epileptic Drugs for Pediatrics Sales by Countries
- 10.1.2 Middle East and Africa Anti-epileptic Drugs for Pediatrics Revenue by Countries
- 10.1.3 GCC Countries
- 10.1.4 Turkey
- 10.1.5 Egypt
- 10.1.6 South Africa
- 10.2 Middle East and Africa Anti-epileptic Drugs for Pediatrics by Product
- 10.3 Middle East and Africa Anti-epileptic Drugs for Pediatrics by End User
11 Company Profiles
- 11.1 Mylan N.V
- 11.1.1 Mylan N.V Company Details
- 11.1.2 Company Business Overview
- 11.1.3 Mylan N.V Anti-epileptic Drugs for Pediatrics Sales, Revenue and Gross Margin (2014-2019)
- 11.1.4 Mylan N.V Anti-epileptic Drugs for Pediatrics Products Offered
- 11.1.5 Mylan N.V Recent Development
- 11.2 Cephalon, Inc
- 11.2.1 Cephalon, Inc Company Details
- 11.2.2 Company Business Overview
- 11.2.3 Cephalon, Inc Anti-epileptic Drugs for Pediatrics Sales, Revenue and Gross Margin (2014-2019)
- 11.2.4 Cephalon, Inc Anti-epileptic Drugs for Pediatrics Products Offered
- 11.2.5 Cephalon, Inc Recent Development
- 11.3 GlaxoSmithKline plc
- 11.3.1 GlaxoSmithKline plc Company Details
- 11.3.2 Company Business Overview
- 11.3.3 GlaxoSmithKline plc Anti-epileptic Drugs for Pediatrics Sales, Revenue and Gross Margin (2014-2019)
- 11.3.4 GlaxoSmithKline plc Anti-epileptic Drugs for Pediatrics Products Offered
- 11.3.5 GlaxoSmithKline plc Recent Development
- 11.4 Janssen Pharmaceuticals
- 11.4.1 Janssen Pharmaceuticals Company Details
- 11.4.2 Company Business Overview
- 11.4.3 Janssen Pharmaceuticals Anti-epileptic Drugs for Pediatrics Sales, Revenue and Gross Margin (2014-2019)
- 11.4.4 Janssen Pharmaceuticals Anti-epileptic Drugs for Pediatrics Products Offered
- 11.4.5 Janssen Pharmaceuticals Recent Development
- 11.5 Novartis AG
- 11.5.1 Novartis AG Company Details
- 11.5.2 Company Business Overview
- 11.5.3 Novartis AG Anti-epileptic Drugs for Pediatrics Sales, Revenue and Gross Margin (2014-2019)
- 11.5.4 Novartis AG Anti-epileptic Drugs for Pediatrics Products Offered
- 11.5.5 Novartis AG Recent Development
- 11.6 Pfizer, Inc
- 11.6.1 Pfizer, Inc Company Details
- 11.6.2 Company Business Overview
- 11.6.3 Pfizer, Inc Anti-epileptic Drugs for Pediatrics Sales, Revenue and Gross Margin (2014-2019)
- 11.6.4 Pfizer, Inc Anti-epileptic Drugs for Pediatrics Products Offered
- 11.6.5 Pfizer, Inc Recent Development
- 11.7 Sanofi S.A
- 11.7.1 Sanofi S.A Company Details
- 11.7.2 Company Business Overview
- 11.7.3 Sanofi S.A Anti-epileptic Drugs for Pediatrics Sales, Revenue and Gross Margin (2014-2019)
- 11.7.4 Sanofi S.A Anti-epileptic Drugs for Pediatrics Products Offered
- 11.7.5 Sanofi S.A Recent Development
- 11.8 UCB Pharma Limited
- 11.8.1 UCB Pharma Limited Company Details
- 11.8.2 Company Business Overview
- 11.8.3 UCB Pharma Limited Anti-epileptic Drugs for Pediatrics Sales, Revenue and Gross Margin (2014-2019)
- 11.8.4 UCB Pharma Limited Anti-epileptic Drugs for Pediatrics Products Offered
- 11.8.5 UCB Pharma Limited Recent Development
- 11.9 Sunovion Pharmaceuticals Limited
- 11.9.1 Sunovion Pharmaceuticals Limited Company Details
- 11.9.2 Company Business Overview
- 11.9.3 Sunovion Pharmaceuticals Limited Anti-epileptic Drugs for Pediatrics Sales, Revenue and Gross Margin (2014-2019)
- 11.9.4 Sunovion Pharmaceuticals Limited Anti-epileptic Drugs for Pediatrics Products Offered
- 11.9.5 Sunovion Pharmaceuticals Limited Recent Development
- 11.10 Valeant Pharmaceuticals International, Inc
- 11.10.1 Valeant Pharmaceuticals International, Inc Company Details
- 11.10.2 Company Business Overview
- 11.10.3 Valeant Pharmaceuticals International, Inc Anti-epileptic Drugs for Pediatrics Sales, Revenue and Gross Margin (2014-2019)
- 11.10.4 Valeant Pharmaceuticals International, Inc Anti-epileptic Drugs for Pediatrics Products Offered
- 11.10.5 Valeant Pharmaceuticals International, Inc Recent Development
- 11.11 Zogenix
- 11.12 GW Pharmaceuticals
- 11.13 Insys
- 11.14 Zynerba
12 Future Forecast
- 12.1 Anti-epileptic Drugs for Pediatrics Market Forecast by Regions
- 12.1.1 Global Anti-epileptic Drugs for Pediatrics Sales Forecast by Regions 2019-2025
- 12.1.2 Global Anti-epileptic Drugs for Pediatrics Revenue Forecast by Regions 2019-2025
- 12.2 Anti-epileptic Drugs for Pediatrics Market Forecast by Product
- 12.2.1 Global Anti-epileptic Drugs for Pediatrics Sales Forecast by Product 2019-2025
- 12.2.2 Global Anti-epileptic Drugs for Pediatrics Revenue Forecast by Product 2019-2025
- 12.3 Anti-epileptic Drugs for Pediatrics Market Forecast by End User
- 12.4 North America Anti-epileptic Drugs for Pediatrics Forecast
- 12.5 Europe Anti-epileptic Drugs for Pediatrics Forecast
- 12.6 Asia Pacific Anti-epileptic Drugs for Pediatrics Forecast
- 12.7 Central & South America Anti-epileptic Drugs for Pediatrics Forecast
- 12.8 Middle East and Africa Anti-epileptic Drugs for Pediatrics Forecast
13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
- 13.1 Market Opportunities and Drivers
- 13.2 Market Challenges
- 13.3 Market Risks/Restraints
- 13.4 Macroscopic Indicators
14 Value Chain and Sales Channels Analysis
- 14.1 Value Chain Analysis
- 14.2 Anti-epileptic Drugs for Pediatrics Customers
- 14.3 Sales Channels Analysis
- 14.3.1 Sales Channels
- 14.3.2 Distributors
15 Research Findings and Conclusion
16 Appendix
- 16.1 Research Methodology
- 16.1.1 Methodology/Research Approach
- 16.1.2 Data Source
- 16.2 Author Details
Summary:
Get latest Market Research Reports on Anti-epileptic Drugs for Pediatrics . Industry analysis & Market Report on Anti-epileptic Drugs for Pediatrics is a syndicated market report, published as Global Anti-epileptic Drugs for Pediatrics Market Insights, Forecast to 2025. It is complete Research Study and Industry Analysis of Anti-epileptic Drugs for Pediatrics market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.
REPORT YOU MIGHT BE INTERESTED
Related Reports
Reason to Buy
Reports and Markets
Contact Us
+1-352-353-0818 (US)Newsletter
KEEP UP TO DATE ON ALL THE LATEST REPORTS
